Christopher Umbricht

Prof. Dr. Christopher Umbricht


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Genome Biology
Verified
Journal Article
Open access
PDF file
ADAnneleen Daemen
Anneleen Daemen
OGObi L Griffith
Obi L Griffith
LHLaura M Heiser
Laura M Heiser
NWNicholas J Wang
Nicholas J Wang
OEOana M Enache
Oana M Enache
JGJoe W Gray
Joe W Gray
Background: First-generation molecular profiles for human breast cancers have enabled the identification of features that can predict therapeutic response; however, little is known about how the various data types can best be combined to yield optimal predictors. Collections of breast cancer cell lines mirror many aspects of breast cancer molecular pathobiology, and measurements of their omic and biological therapeutic responses are well-suited for development of strategies to identify the most predictive molecular feature sets. Results: We used least squares-support vector machines and random forest algorithms to identify molecular features associated with responses of a collection of 70 breast cancer cell lines to 90 experimental or approved therapeutic agents. The datasets analyzed included measurements of copy number aberrations, mutations, gene and isoform expression, promoter methylation and protein expression. Transcriptional subtype contributed strongly to response predictors for 25% of compounds, and adding other molecular data types improved prediction for 65%. No single molecular dataset consistently out-performed the others, suggesting that therapeutic response is mediated at multiple levels in the genome. Response predictors were developed and applied to TCGA data, and were found to be present in subsets of those patient samples. Conclusions: These results suggest that matching patients to treatments based on transcriptional subtype will improve response rates, and inclusion of additional features from other profiling data types may provide additional benefit. Further, we suggest a systems biology strategy for guiding clinical trials so that patient cohorts most likely to respond to new therapies may be more efficiently identified.

1 July 2010 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
RMRadharani Marik
Radharani Marik
MFMaryJo Fackler
MaryJo Fackler
EGEdward Gabrielson
Edward Gabrielson
MZMartha A. Zeiger
Martha A. Zeiger
SSSaraswati Sukumar
Saraswati Sukumar
CUChristopher Umbricht
Christopher Umbricht
F1000Prime Recommended Article: DNA methylation-related vitamin D receptor insensitivity in breast cancer.

1 July 2012 in Epigenetics
Verified
Journal Article
Open access
PDF file
MBMariana Brait
Mariana Brait
MLMyriam Loyo
Myriam Loyo
EREli Rosenbaum
Eli Rosenbaum
KOKimberly L. Ostrow
Kimberly L. Ostrow
AMAlina Markova
Alina Markova
Mohammad Obaidul HoqueMohammad Obaidul Hoque
Mohammad Obaidul Hoque
Our aim was to comprehensively analyze promoter hypermethylation of a panel of novel and known methylation markers for thyroid neoplasms and to establish their relationship with BRAF mutation and clinicopathologic parameters of thyroid cancer. A cohort of thyroid tumors, consisting of 44 cancers and 44 benign thyroid lesions, as well as 15 samples of adjacent normal thyroid tissue, was evaluated for BRAF mutation and promoter hypermethylation. Genes for quantitative methylation specific PCR (QMSP) were selected by a candidate gene approach. Twenty-two genes were tested: TSHR, RASSF1A, RARβ2, DAPK, hMLH1, ATM, S100, p16, CTNNB1, GSTP1, CALCA, TIMP3, TGFßR2, THBS1, MINT1, CTNNB1, MT1G, PAK3, NISCH, DCC, AIM1 and KIF1A. The PCR-based “mutector assay” was used to detect BRAF mutation. All p values reported are two sided. Considerable overlap was seen in the methylation markers among the different tissue groups. Significantly higher methylation frequency and level were observed for KIF1A and RARß2 in cancer samples compared with benign tumors. A negative correlation between BRAF mutation and RASSF1A methylation, and a positive correlation with RARß2 methylation were observed in accordance with previous results. In addition, positive correlation with TIMP3 and a marginal correlation with DCC methylation were observed. The present study constitutes a comprehensive promoter methylation profile of thyroid neoplasia and shows that results must be analyzed in a tissue-specific manner to identify clinically useful methylation markers. Integration of genetic and epigenetic changes in thyroid cancer will help identify relevant biologic pathways that drive its development.

15 May 2011 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
RMRadharani Marik
Radharani Marik
MAMadhan Allu
Madhan Allu
RARavi Anchoori
Ravi Anchoori
VSVered Stearns
Vered Stearns
CUChristopher Umbricht
Christopher Umbricht
SKSaeed Khan
Saeed Khan
The estrogen receptor (ER) is a major target for the treatment of breast cancer cells. Genistein, a soy isoflavone, possesses a structure similar to estrogen and can both mimic and antagonize estrogen effects although at high concentrations it inhibits breast cancer cell proliferation. Hence, to enhance the anti-cancer activity of Genistein at lower concentrations, we have synthesized seven structurally modified derivatives of Genistein (MA-6, MA-8, MA-11, MA-19, MA-20, MA-21 and MA-22) based on the structural requirements for an optimal anti-cancer effect. Among those seven, three derivatives (MA-6, MA-8 and MA-19) showed high antiproliferative activity with IC 50 levels in the range of 1-2.5 μM, i.e., at much lower concentrations range than Genistein itself, in three ER-positive breast cancer cell lines (MCF-7, 21PT and T47D) studied. In our analysis, we noticed that at IC 50 concentrations, the MA-6, MA-8 and MA-19 Genistein derivatives induced apoptosis, inhibited ER-α messenger RNA expression and increased the ratio of ER-β to ER-α levels in a manner comparable to the parent compound Genistein. Of note, these three modified Genistein derivatives exerted their effects at concentrations 10-15 times lower than the parent compound, decreasing the likelihood of significant ER- α pathway activation, which has been a concern for Genistein. Hence these compounds might play a useful role in breast cancer chemoprevention. See commentary: Genistein: The future of prevention and treatment of breast cancer?

17 September 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ZLZhiyang Liu
Zhiyang Liu
ZSZeyad Sahli
Zeyad Sahli
YWYongchun Wang
Yongchun Wang
AWAntonio C. Wolff
Antonio C. Wolff
LCLeslie M. Cope
Leslie M. Cope
CUChristopher Umbricht
Christopher Umbricht

19 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JTJie Tan
Jie Tan
RLRengyun Liu
Rengyun Liu
GZGuangwu Zhu
Guangwu Zhu
CUChristopher Umbricht
Christopher Umbricht
MXMingzhao Xing
Mingzhao Xing
Significance: The use of BRAF V600E-selective inhibitor dabrafenib and MEK inhibitor trametinib is a standard first-line treatment for human cancers harboring BRAF V600E. However, drug resistance/tumor recurrence is common with this treatment and the outcomes are unpredictable. We demonstrate here that dabrafenib and trametinib robustly induce cell apoptosis and hence abolishment of growth/regrowth of cancers harboring both BRAF V600E and TERT promoter mutations with little effect in cells/tumors harboring only BRAF V600E. Thus, TERT promoter mutation, by governing the apoptotic and hence therapeutic sensitivities of BRAF-mutant cancer cells to BRAF/MEK inhibitors, may potentially be useful in helping patient selection for the inhibitor treatment and predicting therapeutic outcomes.